Background
Lung cancer screening using cell-free DNA
First-line IO therapy versus chemotherapy alone
First-line IO combination with chemotherapy versus chemotherapy alone
Trial | IMPower150 | IMPower131 | KEYNOTE-407 | CHECKMATE 227 | |||||
---|---|---|---|---|---|---|---|---|---|
n
| 1202 | 1021 | 559 | 129 | |||||
Selection
| Nonsquamous | Squamous | Squamous | PD-L1 <1%, TMB ≥10 mut/Mb | |||||
Study Arms
| Atezolizumab+ bevacizumab+ carboplatin/paclitaxel | Bevacizumab+ carboplatin/ paclitaxel | Atezolizumab+ carboplatin/ nab-paclitaxel | Carboplatin/ nab-paclitaxel | Pembrolizumab+ carboplatin/ paclitaxel or nab-paclitaxel | Carboplatin/ paclitaxel or nab-paclitaxel | Nivolumab+ ipilimumab | Nivolumab+ chemotherapy | Chemotherapy |
ORR
| 63.5% | 48.0% | 59.4% | 51.3% | 58.4% | 35.0% | 36.8% | 60.5% | 20.8% |
DOR
| 9.0 months | 5.7 months | 6.6 months | 4.4 months | 7.7 months | 4.8 months | NR | 7.4 months | 4.4 months |
PFS
| 8.3 months | 6.8 months | 6.3 months | 5.6 months | 6.4 months | 4.8 months | 7.7 months | 6.2 months | 5.3 months |
OS
| 19.2 months | 14.7 months | 14.0 months | 13.9 months | 15.9 months | 11.3 months | NA | NA | NA |
Grade 3–5 Toxicity
| 58.5% | 50.0% | 68% | 57% | 69.8% | 68.2% | 26%a | 53%a | 36%a |